Inovio Pharmaceuticals (INO) EBITDA Margin (2010 - 2025)

Inovio Pharmaceuticals has disclosed EBITDA Margin across 16 years of filings, most recently posting 38336.97% for Q1 2025.

• In Q1 2025, EBITDA Margin changed N/A year-over-year to 38336.97%; the TTM figure through Dec 2025 stood at 132871.32% (down 8125440.0% YoY), while the FY2025 annual figure was 132871.32%, down 8125440.0% from the prior year.
• EBITDA Margin came in at 38336.97% for Q1 2025 at Inovio Pharmaceuticals, down from 17410.77% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 390.61% in Q3 2022 to a low of 44876.83% in Q4 2022.
• Average EBITDA Margin over 5 years is 23434.95%, with a median of 20553.16% recorded in 2021.
• The largest YoY upside for EBITDA Margin was 2016255 bps in 2022 against a maximum downside of 3230307 bps in 2022.
• Over 5 years, EBITDA Margin stood at 12573.76% in 2021, then plunged by 257 bps to 44876.83% in 2022, then soared by 41 bps to 26686.29% in 2023, then soared by 35 bps to 17410.77% in 2024, then plunged by 120 bps to 38336.97% in 2025.
• Per Business Quant data, the three most recent EBITDA Margin figures were 38336.97% in Q1 2025, 17410.77% in Q4 2024, and 32945.87% in Q2 2024.